Last reviewed · How we verify
Prothrombin time
Prothrombin time (PT) is a laboratory test that measures the time it takes for blood plasma to clot, reflecting the function of extrinsic and common coagulation pathway factors.
Prothrombin time (PT) is a laboratory test that measures the time it takes for blood plasma to clot, reflecting the function of extrinsic and common coagulation pathway factors. Used for Monitoring anticoagulation therapy with warfarin and vitamin K antagonists, Assessment of bleeding risk and coagulation disorders, Evaluation of liver function.
At a glance
| Generic name | Prothrombin time |
|---|---|
| Sponsor | University Hospital, Strasbourg, France |
| Modality | Biologic |
| Therapeutic area | Hematology/Coagulation Monitoring |
| Phase | FDA-approved |
Mechanism of action
PT measures the activity of coagulation factors I, II, V, VII, and X by adding tissue factor and calcium to citrated plasma and timing clot formation. It is primarily used to monitor anticoagulation therapy with warfarin and other vitamin K antagonists, and to assess bleeding risk or liver function. The test is not a drug itself but rather a diagnostic assay used to guide therapeutic decisions.
Approved indications
- Monitoring anticoagulation therapy with warfarin and vitamin K antagonists
- Assessment of bleeding risk and coagulation disorders
- Evaluation of liver function
Common side effects
Key clinical trials
- Goal-Directed Hemostatic Resuscitation Trial in ACLF Induced Coagulopathy (NA)
- Monitoring of Anti-TFPI in Hemophilia
- An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
- Study of Hemostasis in Patients With Congenital Disorder of Glycosylation
- External Multicenter Validation of the APTTO Model for Prolonged APTT Using Clot Waveform Analysis
- Perioperative Outcomes After Neoadjuvant Therapy in Colorectal Cancer
- International Care Bundle Evaluation in Cerebral Hemorrhage Research (PHASE4)
- A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prothrombin time CI brief — competitive landscape report
- Prothrombin time updates RSS · CI watch RSS
- University Hospital, Strasbourg, France portfolio CI